伊沙妥昔单抗联合泊马度胺/地塞米松治疗复发难治多发性骨髓瘤的1b期研究
这项1b期剂量递增研究评估伊沙妥昔单抗联合泊马度胺/地塞米松治疗复发难治多发性骨髓瘤。45例患者接受伊沙妥昔单抗5、10或20 mg/kg,总缓解率62%,中位缓解持续时间18.7个月,中位无进展生存期17.6个月。选择10 mg/kg(每周/每2周)剂量用于未来研究。
要点
- 45例复发难治多发性骨髓瘤患者接受伊沙妥昔单抗联合泊马度胺/地塞米松,总缓解率62%。
- 中位缓解持续时间18.7个月,中位无进展生存期17.6个月。
- 最常见≥3级治疗中出现的不良事件为肺炎,发生于8例患者(17.8%)。
核心结论
- 伊沙妥昔单抗联合泊马度胺/地塞米松在经重度治疗的复发难治多发性骨髓瘤患者中显示出潜在有意义的临床活性和可控的安全性。
- 选择伊沙妥昔单抗10 mg/kg(每周给药4周后每2周给药)剂量用于未来研究。
研究设计与样本
- 1b期剂量递增研究,纳入接受过≥2线既往MM治疗(包括来那度胺和蛋白酶体抑制剂)的复发难治多发性骨髓瘤患者。
- 45例患者接受伊沙妥昔单抗5 mg/kg(n=8)、10 mg/kg(n=31)或20 mg/kg(n=6),联合泊马度胺4 mg(第1-21天)和地塞米松40 mg(每周),28天为一周期,直至疾病进展或不耐受毒性。
- 主要目标为确定安全性和伊沙妥昔单抗联合方案的推荐剂量,次要目标包括药代动力学、免疫原性和疗效。
主要发现
- 患者既往中位治疗线数为3(范围1-10),91%对末次方案难治,82%来那度胺难治,84%蛋白酶体抑制剂难治。
- 中位治疗持续时间9.6个月,19例患者(42%)仍在治疗中。
- 最常见不良事件包括乏力(62%)、上呼吸道感染(42%)、输注反应(42%)和呼吸困难(40%)。
- 最常见≥3级治疗中出现的不良事件为肺炎,发生于8例患者(17.8%)。
- 血液学实验室异常常见:淋巴细胞减少、白细胞减少、贫血各98%,中性粒细胞减少93%,血小板减少84%。
关键数值与推荐
- 伊沙妥昔单抗给药方案:5、10或20 mg/kg,每周给药4周后每2周给药。
- 泊马度胺4 mg(第1-21天),地塞米松40 mg(每周),28天为一周期。
- 选择伊沙妥昔单抗10 mg/kg(每周/每2周)剂量用于未来研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior MM therapies, including lenalidomide and a proteasome inhibitor (PI), were enrolled and received isatuximab at 5, 10, or 20 mg/kg (weekly for 4 weeks, followed by every 2 weeks), pomalidomide 4 mg (days 1-21), and dexamethasone 40 mg (weekly) in 28-day cycles until progression/intolerable toxicity. The primary objective was to determine the safety and recommended dose of isatuximab with this combination. Secondary objectives included evaluation of pharmacokinetics, immunogenicity, and efficacy. Forty-five patients received isatuximab (5 [n = 8], 10 [n = 31], or 20 [n = 6] mg/kg). Patients received a median of 3 (range, 1-10) prior lines; most were refractory to their last regimen (91%), with 82% lenalidomide-refractory and 84% PI-refractory. Median treatment duration was 9.6 months; 19 patients (42%) remain on treatment. Most common adverse events included fatigue (62%), and upper respiratory tract infection (42%), infusion reactions (42%), and dyspnea (40%). The most common grade ≥3 treatment-emergent adverse event was pneumonia, which occurred in 8 patients (17.8%). Hematologic laboratory abnormalities were common (lymphopenia, leukopenia, anemia, 98% each; neutropenia, 93%; and thrombocytopenia, 84%). Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months. These results demonstrate potential meaningful clinical activity and a manageable safety profile of isatuximab plus pomalidomide/dexamethasone in heavily pretreated patients with RRMM. The 10 mg/kg weekly/every 2 weeks isatuximab dose was selected for future studies. This trial was registered at www.clinicaltrials.gov as #NCT02283775.
引用
- Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019. PMID: 30862646. doi:10.1182/blood-2019-02-895193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。